Advances in the treatment of type 2 diabetes: impact of dulaglutide

References

• International Diabetes Federation IDF Diabtes Atlas 6th ed Brussels, Belgium International Diabetes Federation 2014 Available from: http://www.idf.org/diabetesatlas/update-2014 Accessed August 8, 2015
   Google Scholar
• Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, GA US Department of Health and Human Services 2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf Accessed August 8, 2015
   Google Scholar
• Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773 795 19336687
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2015 Diabetes Care 2015 38 Suppl 1 S1 S93
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI AACE/ACE comprehensive diabetes management algorithm 2015 Endocr Pract 2015 21 438 447 25877012
   PubMed Web of Science ®Google Scholar
• Handelsman Y Bloomgarden ZT Grunberger G American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015 Endocr Pract 2015 21 Suppl 1 1 87 25869408
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Cefalu WT Buse JB Del Prato S Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors’ expert forum Diabetes Care 2014 37 2647 2659 25147257
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S Fradkin JE Saydah SH Rust KF Cowie CC The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010 Diabetes Care 2013 36 2271 2279 23418368
   PubMed Web of Science ®Google Scholar
• Green JB Bethel MA Armstrong PW Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 373 232 242 26052984
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 1327 1335 23992602
   PubMed Web of Science ®Google Scholar
• Pfeffer M The evaluation of lixisenatide in acute coronary syndrome – the results of ELIXA Poster presented at: American Diabetes Association 2015 Scientific Sessions June 8, 2015 Boston, MA
   Google Scholar
• Eli Lilly and Company The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: researching cardiovascular events with a weekly incretin in diabetes (REWIND) Available from: http://clinicaltrials.gov/show/NCT01394952 NLM identifier: NCT01394952 Accessed November 4, 2015
   Google Scholar
• Ou SM Shih CJ Chao PW Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus Ann Intern Med 2015 163 663 672 26457538
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med Epub 2015 9 17
   PubMed Web of Science ®Google Scholar
• Grandy S Fox KM Hardy E Group SS Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) Curr Ther Res Clin Exp 2013 75 77 82 24465048
   PubMedGoogle Scholar
• Turner LW Nartey D Stafford RS Singh S Alexander GC Ambulatory treatment of type 2 diabetes in the US, 1997–2012 Diabetes Care 2014 37 985 992 24198301
   PubMed Web of Science ®Google Scholar
• Trujillo JM Nuffer W GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents Pharmacotherapy 2014 34 11 1174 1186 25382096
   PubMed Web of Science ®Google Scholar
• Trulicity^® (dulaglutide) for injection [package insert] Indianapolis Eli Lily 2015
   Google Scholar
• Victoza^® (liraglutide) for injection [package insert] Bagsvaerd, Denmark Novo Nordisk 2015
   Google Scholar
• Tanzeum^® (albiglutide) for injection [package insert] Wilmington, DE GlaxoSmithKline 2015
   Google Scholar
• Byetta^® (exenatide) for injection [package insert] Wilmington, DE AstraZeneca Pharmaceuticals 2015
   Google Scholar
• Bydureon^® (exenatide extended-release) for injectable suspension [package insert] Wilmington, DE AstraZeneca Pharmaceuticals 2015
   Google Scholar
• Barrington P Chien JY Tibaldi F Showalter HD Schneck K Ellis B LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects Diabetes Obes Metab 2011 13 434 438 21251179
   PubMed Web of Science ®Google Scholar
• Barrington P Chien JY Showalter HD A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes Diabetes Obes Metab 2011 13 426 433 21251178
   PubMed Web of Science ®Google Scholar
• Umpierrez GE Blevins T Rosenstock J Cheng C Anderson JH Bastyr EJ3rd The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study Diabetes Obes Metab 2011 13 418 425 21251180
   PubMed Web of Science ®Google Scholar
• Grunberger G Chang A Garcia Soria G Botros FT Bsharat R Milicevic Z Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study Diabet Med 2012 29 1260 1267 22804250
   PubMed Web of Science ®Google Scholar
• Terauchi Y Satoi Y Takeuchi M Imaoka T Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study Endocr J 2014 61 949 959 25029955
   PubMed Web of Science ®Google Scholar
• Umpierrez G Tofé Povedano S Pérez Manghi F Shurzinske L Pechtner V Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 2014 37 2168 2176 24842985
   PubMed Web of Science ®Google Scholar
• Nauck M Weinstock RS Umpierrez GE Guerci B Skrivanek Z Milicevic Z Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care 2014 37 2149 2158 24742660
   PubMed Web of Science ®Google Scholar
• Dungan KM Povedano ST Forst T Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 2014 384 1349 1357 25018121
   PubMed Web of Science ®Google Scholar
• Wysham C Blevins T Arakaki R Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 2014 37 2159 2167 24879836
   PubMed Web of Science ®Google Scholar
• Giorgino F Benroubi M Sun JH Zimmermann AG Pechtner V Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) Diabetes Care Epub 2015 6 18
   PubMed Web of Science ®Google Scholar
• Blonde L Jendle J Gross J Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study Lancet 2015 385 2057 2066 26009229
   PubMed Web of Science ®Google Scholar
• Weinstock RS Guerci B Umpierrez G Nauck MA Skrivanek Z Milicevic Z Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study Diabetes Obes Metab 2015 17 849 858 25912221
   PubMed Web of Science ®Google Scholar
• Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 150 156 21334333
   PubMed Web of Science ®Google Scholar
• Eli Lilly Trulicity REMS (risk evaluation and mitigation strategy) Available from: http://www.trulicityrems.com Accessed August 10, 2015
   Google Scholar
• Gallwitz B Extra-pancreatic effects of incretin-based therapies Endocrine 2014 47 360 371 24604239
   PubMed Web of Science ®Google Scholar
• Ferdinand KC White WB Calhoun DA Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus Hypertension 2014 64 731 737 24980665
   PubMed Web of Science ®Google Scholar
• Fu AZ Qiu Y Radican L Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes Curr Med Res Opin 2009 25 1413 1420 19422281
   PubMed Web of Science ®Google Scholar
• Barbosa CD Balp MM Kulich K Germain N Rofail D A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence Patient Prefer Adherence 2012 6 39 48 22272068
   PubMed Web of Science ®Google Scholar
• Ross SA Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes Am J Med 2013 126 S38 S48 23953078
   PubMed Web of Science ®Google Scholar
• Eli Lilly Instructions for use: Trulicity (dulaglutide) Available from: http://pi.lilly.com/us/trulicity-highdose-ai-ifu.pdf 2014 Accessed August 10, 2015
   Google Scholar
• Matfin G Van Brunt K Zimmermann AG Threlkeld R Ignaut DA Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes J Diabetes Sci Technol 2015 9 1071 1079 25901022
   PubMedGoogle Scholar
• Reaney M Yu M Lakshmanan M Pechtner V van Brunt K Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials Diabetes Obes Metab 2015 17 896 903 26095190
   PubMed Web of Science ®Google Scholar
• Giorgino F Benroubi M Sun J Efficacy and safety of once-weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) Diabetologia 2014 57 Suppl 1 A38
   Google Scholar
• Truven Health Analytics Red Book: a comprehensive, consistent drug pricing resource Available from: http://micromedex.com/redbook Accessed November 13, 2015
   Google Scholar